BPMC Forex-Nachrichten
Blueprint Medicines Says FDA Places Partial Clinical Hold On Phase 1/2 VELA Trial Of BLU-222
Precision therapy company Blueprint Medicines Corp. (BPMC) announced Friday that the U.S. Food and Drug Administration (FDA) verbally informed the company on Wednesday that it has placed a partial clinical hold on the Phase 1/2 VELA trial of BLU-222 due to visual adverse events (AEs) observed in a limited number of patients.
RTTNews
|
vor 734 Tagen
